For instance, low-grade serous ovarian cancer (LGSOC), endometrioid, mucinous (MUCOC) and clear cell, are often detected at an early stage (FIGO I–II) and have more stable genomes, and are characterised by specific somatic mutations: LGSOC with KRAS and BRAF, endometrioid with PTEN and PI3KCA, MUCOC with TP53 and KRAS, and clear cell with PI3KCA and ARID1A. This evidence concerns the gene KRAS and ovarian serous adenocarcinoma.